JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Incyte told JP Morgan attendees of plans for four launches in 2025, beginning with its FDA-approved Niktimvo for chronic GVHD.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

As part of the restructuring, Diamond has received a $39 million “stalking horse” bid from an affiliate of Universal ...

JPMorgan Chase's annual profit rose to a record as its dealmakers and traders reaped a windfall from rebounding markets in ...

South Korea’s two leading biopharmaceutical companies, Samsung Biologics and Celltrion, unveiled ambitious plans to enter the ...

It's not just JPMorgan Chase. Across the industry, banks are rethinking their remote-work policies — but experts say it won't ...